Pacific Biosciences of California, Inc. (PACB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.42+1.11 (+3.06%)
At close: 4:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 36.31 |
| Open | 35.69 |
| Bid | 37.10 x 1400 |
| Ask | 37.60 x 800 |
| Day's Range | 35.10 - 37.76 |
| 52 Week Range | 2.20 - 41.65 |
| Volume | 3,505,213 |
| Avg. Volume | 4,894,161 |
| Market Cap | 7.006B |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 |
| Earnings Date | Feb 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.25 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Zacks
Why You Should Retain Pacific Biosciences (PACB) Stock Now
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.
- TheStreet.com
Pacific Biosciences Reaches Our Price Target: Now What?
"This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . In the daily Japanese candlestick chart of PACB, below, we can see that the shares corrected modestly after our Dec. 9 review and subsequently rallied to the $39 price target. This chart shows that prices are above the rising 50-day moving average line and trade at more than three times the level of the rising 200-day moving average line.
- Zacks
Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues
Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.
© 2021 Verizon Media. All rights reserved.
